CAR T-Cell Therapy

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat B-cell malignancies:

• BREYANZI™ For adult patients with:
  • Relapsed or refractory (R/R) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B and are refractory to first-line chemoimmunotherapy, relapsed within 12 months of first-line chemoimmunotherapy or after two or more lines of systemic therapy.
  • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
  • Relapsed or refractory (R/R) mantle cell lymphoma after two or more lines of systemic therapy, including a BTK inhibitor.
  • Relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), after two or more lines of systemic therapy, including a BTK inhibitor and a BCL-2 inhibitor.

• KYMRIAH^® For adult patients with:
  • Relapsed or refractory (R/R) large B-cell lymphoma, including DLBCL not otherwise specified, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma, and after two or more lines of systemic therapy.
  • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.

• TECARTUS™ For adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

• YESCARTA^® For adult patients with:
  • Relapsed or refractory (R/R) large B-cell lymphoma, refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy.
  • Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy. 
  • Relapsed or refractory (R/R) aggressive large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma (FL), and after two or more lines of systemic therapy.

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat acute lymphoblastic leukemia (ALL):

• AUCATZYL^®: For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  • CAR T product is given in 2 doses - the treatment regimen consists of a split dose infusion to be administered on Day 1 and Day 10 (± 2 days) (2.1). Dose to be administered is determined by the patient's bone marrow blast assessment.
• KYMRIAH^®: For patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL) where ALL is refractory or in a second or later relapse.


• TECARTUS^™: For adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).

Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat multiple myeloma:

• ABECMA^®: For adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
  
  *Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.


• CARVYKTI^®: For adult patients with relapsed or refractory (R/R) multiple myeloma after one (1) or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and are refractory to lenalidomide.
  
  *Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.